CytomX Therapeutics Ownership | Who Owns CytomX Therapeutics?
CytomX Therapeutics Ownership Summary
CytomX Therapeutics is owned by 27.01% institutional investors, 0.87% insiders, and 72.12% retail investors. Vr adviser is the largest institutional shareholder, holding 12.06% of CTMX shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.07% of its assets in CytomX Therapeutics shares.
CTMX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | CytomX Therapeutics | 27.01% | 0.87% | 72.12% |
| Sector | Healthcare Stocks | 232.86% | 10.65% | -143.51% |
| Industry | Biotech Stocks | 382.13% | 10.41% | -292.54% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vr adviser | 15.56M | 12.06% | $49.64M |
| Fmr | 15.40M | 11.93% | $49.11M |
| Tang capital management | 11.07M | 8.57% | $35.30M |
| Perceptive advisors | 9.68M | 7.50% | $30.88M |
| Orbimed advisors | 8.46M | 6.56% | $26.99M |
| Commodore capital lp | 7.69M | 5.96% | $24.54M |
| Vanguard group | 8.48M | 5.14% | $36.11M |
| Millennium management | 3.22M | 3.79% | $3.32M |
| Baker bros. advisors lp | 4.25M | 3.29% | $13.56M |
| Balyasny asset management | 2.87M | 3.29% | $6.50M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Vr adviser | 15.56M | 2.79% | $49.64M |
| Exome asset management | 745.30K | 1.44% | $2.38M |
| Tang capital management | 11.07M | 1.36% | $35.30M |
| Adar1 capital management | 4.05M | 1.21% | $12.90M |
| Commodore capital lp | 7.69M | 1.20% | $24.54M |
| Ikarian capital | 3.37M | 1.09% | $10.76M |
| Perceptive advisors | 9.68M | 0.89% | $30.88M |
| Cannon global investment management | 96.10K | 0.88% | $451.67K |
| Kynam capital management, lp | 3.65M | 0.87% | $11.63M |
| Vivo capital | 2.88M | 0.74% | $9.20M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 15.40M | 0.00% | 6.16M |
| State street | 5.14M | 0.00% | 4.50M |
| Ikarian capital | 3.37M | 1.09% | 3.37M |
| Balyasny asset management | 2.87M | 0.01% | 2.87M |
| Perceptive advisors | 9.68M | 0.89% | 2.69M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Franklin resources | - | - | -5.77M |
| Bvf inc/il | - | - | -5.23M |
| Janus henderson group | - | - | -4.81M |
| Point72 asset management | 4.07M | 0.02% | -4.02M |
| Fairmount funds management | - | - | -3.90M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Ikarian capital | 3.37M | 1.09% | 3.37M | $10.76M |
| Balyasny asset management | 2.87M | 0.01% | 2.87M | $6.50M |
| Boothbay fund management | 1.24M | 0.06% | 1.24M | $3.95M |
| Exome asset management | 745.30K | 1.44% | 745.30K | $2.38M |
| Inspire investing | 522.48K | 0.16% | 522.48K | $1.67M |
Sold Out
| Holder | Change |
|---|---|
| Innealta capital | -2.00 |
| Raleigh capital management | -250.00 |
| Old point trust & financial services n a | -250.00 |
| Bell investment advisors | -388.00 |
| Federated hermes | -398.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 70 | -37.50% | 44,567,168 | -67.59% | 27 | 0.39% | 42 | -32.26% | 16 | -38.46% |
| Sep 30, 2025 | 36 | -59.09% | 16,872,803 | -87.34% | 13 | 0.12% | 20 | -64.91% | 7 | -58.82% |
| Jun 30, 2025 | 88 | 35.38% | 133,304,249 | 195.10% | 153 | 5.69% | 57 | 128.00% | 16 | -36.00% |
| Mar 31, 2025 | 66 | -7.04% | 45,273,213 | -3.09% | 51 | 1.72% | 26 | -25.71% | 25 | 19.05% |
| Dec 31, 2024 | 70 | -2.78% | 46,332,988 | -9.49% | 54 | 1.50% | 34 | 21.43% | 21 | -12.50% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard US Total Market Shares ETF | 2.46M | 3.07% | - |
| Vanguard Total Stock Mkt Idx Inv | 6.53M | 3.02% | 1.74M |
| State Street® SPDR® S&P® Biotech ETF | 4.51M | 2.09% | 67.83K |
| Franklin Biotechnology Discv A(acc)USD | 2.92M | 1.77% | -800.28K |
| Fidelity Select Health Care | 3.40M | 1.57% | - |
| Fidelity Small Cap Growth | 3.28M | 1.52% | - |
| Fidelity Stock Selector Small Cap | 3.22M | 1.49% | 87.80K |
| Fidelity Series Small Cap Opps | 2.53M | 1.17% | - |
| FIAM Small Cap Core CIT Cl B | 2.49M | 1.15% | - |
| FIAM Small Cap Core Composite | 2.49M | 1.15% | 1.40M |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 17, 2026 | Chu Yu-Waye | Chief Medical Officer | Sell | $136.68K |
| Mar 17, 2026 | McCarthy Sean A. | CEO | Sell | $764.14K |
| Mar 17, 2026 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | $202.27K |
| Mar 17, 2026 | Ogden Christopher | Chief Financial Officer | Sell | $124.11K |
| Nov 06, 2025 | McCarthy Sean A. | CEO | Sell | $461.91K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 4 |
| 2025 Q4 | - | 1 |
| 2025 Q3 | - | - |
| 2025 Q2 | - | 4 |
| 2025 Q1 | - | 5 |
CTMX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools